webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

SC-VC-PAB-DM1

  CAS No.: 2259318-47-1   Cat No.: BADC-00668 4.5  

SC-VC-PAB-DM1 is a drug-linker conjugate for ADC with with potent antitumor activity by using DM1 (Mertansine, a tubulin inhibitor) , linked via the ADC linker SC-VC-PAB.

SC-VC-PAB-DM1

Structure of 2259318-47-1

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin with Linker
Molecular Formula
C61H82ClN9O19
Molecular Weight
1280.81
Shipping
Room temperature

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
IUPAC Name
(2,5-dioxopyrrolidin-1-yl) 6-[[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-[[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylcarbamoyl]oxymethyl]anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-6-oxohexanoate
Canonical SMILES
C[C@]12[C@H]([C@@H]([C@](O3)([H])C[C@]([C@](/C=C/C=C(C)/CC4=CC(N(C)C(C[C@]2([H])OC([C@H](C)N(C)C(OCC5=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCC(ON6C(CCC6=O)=O)=O)=O)=O)=O)C=C5)=O)=O)=O)=C(C(OC)=C4)Cl)([H])OC)(NC3=O)O)C)O1
InChI
InChI=1S/C61H82ClN9O19/c1-33(2)52(67-46(72)18-11-12-19-50(76)90-71-47(73)24-25-48(71)74)55(78)66-40(16-14-26-64-57(63)80)54(77)65-39-22-20-37(21-23-39)32-86-59(82)69(7)36(5)56(79)88-45-30-49(75)70(8)41-28-38(29-42(84-9)51(41)62)27-34(3)15-13-17-44(85-10)61(83)31-43(87-58(81)68-61)35(4)53-60(45,6)89-53/h13,15,17,20-23,28-29,33,35-36,40,43-45,52-53,83H,11-12,14,16,18-19,24-27,30-32H2,1-10H3,(H,65,77)(H,66,78)(H,67,72)(H,68,81)(H3,63,64,80)/b17-13+,34-15+/t35-,36+,40+,43+,44-,45+,52+,53+,60+,61+/m1/s1
Shipping
Room temperature
1.ROR1 ANTIBODY IMMUNOCONJUGATES
LANNUTTI, Brian, et al.
Cancer is the second leading cause of human death next to coronary artery disease.Receptor tyrosine kinases (RTKs) play a key role in oncogenic transformation, growth andmetastases. RTKs regulate cell differentiation, proliferation, migration, angiogenesis, andsurvival. The receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an evolutionarilyconserved type I membrane protein that belongs to the ROR subfamily and has extracellulardomains that contain immunoglobulin (Ig)-like, Frizzled, and Kringle domains. ROR 1-deficientmice display a variety of phenotypic defects within the skeletal and urogenital systems, as wellas postnatal growth retardation. ROR1 is expressed during embryogenesis and by a variety ofdifferent cancers, but not by normal post-partum tissues, and can be considered an oncoembryonic surface antigen. Functional data suggest that ROR1 may function in non-canonicalWNT-signaling to promote the survival of malignant cells.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload ADC Linker–Payload Conjugation ADC Linker Development Chemical Payload Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Linkers - A Crucial Factor in Antibody–Drug Conjugates Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: NHS-SS-biotin | Biotin-PEG4-PFP ester | Biotin-PEG4-SS-Alkyne | FR-901464 | MCC-DM1 | MCC-Modified Daunorubicinol | MAC glucuronide phenol-linked SN-38 | MAC glucuronide α-hydroxy lactone-linked SN-38 | NH2-PEG4-VC-PAB-DMEA-SN38 | Cantuzumab mertansine | SC-VC-PAB-DM1
Send Inquiry
Verification code
Inquiry Basket